<?xml version="1.0" encoding="UTF-8"?>
<p id="p0375">Several conventional anticancer drugs for patients were and are extracted from plants. These include vincristine, paclitaxel, and camptothecin, all of which have been approved by the U.S. Food and Drug Administration (
 <xref rid="bib14" ref-type="bibr">Dholwani et al., 2008</xref>). Moreover, some TCMs have been proved to have good anticancer activity in laboratory and clinical trials. The potential anticancer and antiangiogenesis properties of 
 <italic>A. lancea</italic> extract and its major constituents have been demonstrated in various cancer, for examples, murine blastoma cells Hela (human cervical cells), SGC-7901 (human gastric cancer cells), BEL-7402 (human liver cancer cells), H33, S180, HL-60 leukemic cells, and gastric cancer (
 <xref rid="bib69" ref-type="bibr">Masuda et al., 2015</xref>; 
 <xref rid="bib141" ref-type="bibr">Zhao et al., 2014</xref>). In recent years, 
 <italic>A. lancea</italic> especially as an alternative treatment for cholangiocarcinoma (CCA) patients, seems to be a promising candidate herbal medicine. Results from a series of studies (
 <xref rid="bib74" ref-type="bibr">Na-Bangchang et al., 2017</xref>) confirm anti-CCA potential and safety profiles of both the crude extract and the finished product (oral pharmaceutical formulation of the standardized 
 <italic>A. lancea</italic> extract). Phases I and II clinical trials of the product to confirm tolerability and efficacy in healthy subjects and patients with advanced-stage CCA will be carried out soon. AR ethanol extract exhibited an inhibitory effect on opisthorchis viverrini (OV)-induced CCA animal without obvious toxicity after oral administration for 30 days (
 <xref rid="bib81" ref-type="bibr">Ohara et al., 2018</xref>).
</p>
